Brachytherapy boost fails to improve biochemical control over 80 Gy EBRT in intermediate-risk prostate cancer
In phase III GETUG P05, brachytherapy boost did not improve 5-year biochemical control over dose-escalated EBRT to 80 Gy in intermediate-risk prostate cancer and increased mild-to-moderate urinary toxicity.